Brief Introduction

Beijing Hotgen Biotech Co.,Ltd (Briefed as Hotgen, Stock code: 688068)was founded in 2005 and located in Biomedical Base of Zhongguancun High-Tech Park in Beijing, is a high-tech Bio-medical enterprise engaged in research and development, manufacture, marketing and services of in vitro diagnostic reagents and instruments. With the mission of “developing better biotechnology for human health” and adhering to the concept of “Advanced Diagnostics Attributed from Our efforts”, we continue to focus on the innovation and industrialization of products in the field of medical and public safety.The company's main products are in vitro diagnostic reagents and instruments, mainly used in clinical medical fields such as liver cancer, cardiovascular and cerebrovascular diseases, inflammatory infections, and public safety fields such as biosafety, food safety, and disease control emergency.

 

Company Overview

Full name Beijing Hotgen Biotech Co., Ltd.
Abbreviations Hotgen
Code 688068
Founded 23 June 2005
Listing 30 September 2019
Domicile Shanghai
Website www.hotgen.com.cn
Email hotgen@hotgen.com.cn
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No

Financials

Highlights

  2020 2019 2018
Earnings Per Share 1.80 0.67 1.03
R&D expenditure as a % of operating revenue 9.27% 13.78% 9.82%
Operating Revenue 513.53 210.41 187.12
Net Income 111.30 33.75 48.19

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 513.53 210.41 187.12
Operating Costs 189.95 56.55 49.13
Operating Income 513.53 210.41 187.12
Pretax Income 528.94 216.72 192.73
Income Tax 16.13 4.11 7.31
Net Income 111.30 33.75 48.19

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Assets
Current Assets-Total 587.77 549.22 129.94
Non-current Assets-Total 314.74 176.46 137.18
Total Assets 902.52 725.67 267.12
Liabilities
Current Liabilities-Total 144.11 45.52 56.11
Non-current Liabilities-Total 11.61 30.85 0.57
Total Liabilities 155.72 76.37 56.68
Stockholder's Equity
Share Capital 62.20 62.20 46.65
Retained Profits 230.85 137.44 103.56
Total Owners' Equity 746.79 649.30 210.44

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 164.62 19.37 55.04
Net Cash Flows-Investing -164.10 -85.86 -40.58
Net Cash Flows-Financing -42.16 425.44 0.44

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
林长青 14.65 23.55%
周锌 6.44 10.35%
同程热景 3.74 6.01%
浙江大健康 3.48 5.60%
达晨创泰 2.09 3.36%
达晨创恒 2.04 3.28%
张辉阳 1.87 3.00%
云集财富 1.80 2.89%
达晨创瑞 1.69 2.71%
海达睿盈 1.52 2.44%
As of 2020-12-31

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.